The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus.
Bates, Ruth L. Payne, Sarah J. Drury, S.L. Nelson, Paul N. Isenberg, D.A. Murphy, John J. Frampton, Geoffrey
Bates, Ruth L.
Payne, Sarah J.
Drury, S.L.
Nelson, Paul N.
Isenberg, D.A.
Murphy, John J.
Frampton, Geoffrey
Editors
Other contributors
Affiliation
Epub Date
Issue Date
2003
Submitted date
Alternative
Abstract
We have recently described the novel autoantigen plasminogen activator inhibitor (PAI-1) in systemic lupus erythematosus (SLE). The aim of this study was to determine the prevalence and clinical significance of anti-PAI-1 autoantibodies in patients with SLE. Autoantibodies to recombinant PAI-1 were measured in retrospective sera of 48 lupus patients by immunoassay in order to assess their clinical significance. This showed that 71% of sera from 48 lupus patients had significantly elevated anti-PAI-1 autoantibodies as compared with normal control subjects (P < 0.0001). There was a weak but significant (P < 0.043) correlation with anti-dsDNA autoantibodies. In longitudinal studies, autoantibodies against PAI-1 correlated with clinical parameters measured by the BILAG disease activity index including global clinical score. Our study demonstrates the high frequency of novel autoantibodies to PAI-1 in patients with lupus. The serial clinical correlations with anti-PAI-1 autoantibodies also support the hypothesis that these autoantibodies may play a pathogenic role in lupus.
Citation
Lupus 2003, 12(8): 617-622
Publisher
Journal
Research Unit
PubMed ID
12945721
PubMed Central ID
Embedded videos
Type
Journal article
Language
en
Description
Metadata record only
Series/Report no.
ISSN
0961-2033